Search

Your search keyword '"Fillit, Howard"' showing total 8 results
Start Over Author "Fillit, Howard" Publisher ios press
8 results on '"Fillit, Howard"'

2. Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review

Author

Aigbogun, Myrlene Sanon, primary, Cloutier, Martin, additional, Gauthier-Loiselle, Marjolaine, additional, Guerin, Annie, additional, Ladouceur, Martin, additional, Baker, Ross A., additional, Grundman, Michael, additional, Duffy, Ruth A., additional, Hartry, Ann, additional, Gwin, Keva, additional, and Fillit, Howard, additional

Published
2020
Full Text
View/download PDF

6. Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.

Author

Black, Christopher M., Fillit, Howard, Lin Xie, Xiaohan Hu, Kariburyo, M. Furaha, Ambegaonkar, Baishali M., Baser, Onur, Yuce, Huseyin, Khandker, Rezaul K., Xie, Lin, and Hu, Xiaohan

Subjects
*ALZHEIMER'S disease, *CLINICAL trials, *DEMENTIA, *DISEASE progression, *PUBLIC health
Abstract

Background: Current information is scarce regarding comorbid conditions, treatment, survival, institutionalization, and health care utilization for Alzheimer's disease (AD) patients.Objectives: Compare all-cause mortality, rate of institutionalization, and economic burden between treated and untreated newly-diagnosed AD patients.Methods: Patients aged 65-100 years with ≥1 primary or ≥2 secondary AD diagnoses (ICD-9-CM:331.0] with continuous medical and pharmacy benefits for ≥12 months pre-index and ≥6 months post-index date (first AD diagnosis date) were identified from Medicare fee-for-service claims 01JAN2011-30JUN2014. Patients with AD treatment claims or AD/AD-related dementia diagnosis during the pre-index period were excluded. Patients were assigned to treated and untreated cohorts based on AD treatment received post-index date. Total 8,995 newly-diagnosed AD patients were identified; 4,037 (44.8%) were assigned to the treated cohort. Time-to-death and institutionalization were assessed using Cox regression. To compare health care costs and utilizations, 1 : 1 propensity score matching (PSM) was used.Results: Untreated patients were older (83.85 versus 81.44 years; p < 0.0001), with more severe comorbidities (mean Charlson comorbidity index: 3.54 versus 3.22; p < 0.0001). After covariate adjustment, treated patients were less likely to die (hazard ratio[HR] = 0.69; p < 0.0001) and were associated with 20% lower risk of institutionalization (HR = 0.801; p = 0.0003). After PSM, treated AD patients were less likely to have hospice visits (3.25% versus 9.45%; p < 0.0001), and incurred lower annual all-cause costs ($25,828 versus $30,110; p = 0.0162).Conclusion: After controlling for comorbidities, treated AD patients have better survival, lower institutionalization, and sometimes fewer resource utilizations, suggesting that treatment and improved care management could be beneficial for newly-diagnosed AD patients from economic and clinical perspectives. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

7. Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia

Author

Andrieu, Sandrine, primary, Coley, Nicola, additional, Aisen, Paul, additional, Carrillo, Maria C., additional, DeKosky, Steven, additional, Durga, Jane, additional, Fillit, Howard, additional, Frisoni, Giovanni B., additional, Froelich, Lutz, additional, Gauthier, Serge, additional, Jones, Roy, additional, Jönsson, Linus, additional, Khachaturian, Zaven, additional, Morris, John C., additional, Orgogozo, Jean-Marc, additional, Ousset, Pierre-Jean, additional, Robert, Philippe, additional, Salmon, Eric, additional, Sampaio, Cristina, additional, Verhey, Frans, additional, Wilcock, Gordon, additional, and Vellas, Bruno, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results